Drug Shortage Report for DALACIN C 300 MG
Report ID | 118995 |
Drug Identification Number | 02182866 |
Brand name | DALACIN C 300 MG |
Common or Proper name | DALACIN C 300MG |
Company Name | PFIZER CANADA ULC |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | CLINDAMYCIN |
Strength(s) | 300MG |
Dosage form(s) | CAPSULE |
Route of administration | ORAL ORAL |
Packaging size | 100 BTL |
ATC code | J01FF |
ATC description | MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2020-06-30 |
Estimated end date | |
Actual end date | 2020-08-25 |
Shortage status | Resolved |
Updated date | 2020-08-26 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 17300 TRANS-CANADA HIGHWAY KIRKLAND, QUEBEC CANADA H9J 2M5 |
Company contact information | Customer Service / service à la clientèle : 1-888-999-8750 Email / courriel: PharmaCustomerServiceDept@pfizer.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2020-06-26 | English | Compare |
v2 | 2020-06-26 | French | Compare |
v3 | 2020-07-01 | English | Compare |
v4 | 2020-08-19 | English | Compare |
v5 | 2020-08-19 | French | Compare |
v6 | 2020-08-26 | English | Compare |
v7 | 2020-08-26 | French | Compare |
Showing 1 to 7 of 7